DeLaRosa supports bill mandating 12-month hormone therapy coverage

Rep. Margaret A. DeLaRosa (D-42nd) cast a Yes vote for HB5492 during the 104th General Assembly on May 31, 2026, legislative records from the Illinois House show. The measure passed with a vote of 75-39.

The bill synopsis identified its main focus as "PRESCRIPTION HORMONE THERAPY."

The information below reflects analysis derived from the bill's language and may include interpretation for clarification.

Beginning Jan. 1, 2028, the legislation will require most Illinois health insurers, including plans covering state employees and Medicaid recipients, to fund up to a 12-month supply of prescription hormone therapy and related self-administration items when authorized by an in-network prescriber and dispensed simultaneously. The bill excludes glucagon-like peptide-1 therapies from its scope, permits insurers to use drug management protocols and limit fill amounts at year-end after a 12-month supply, and compels coverage arrangements for out-of-network providers when in-network access is unavailable. Pharmacists and dispensing providers, with outlined exceptions, must fill up to a 12-month supply upon patient request.

The legislative record for HB5492 notes 'Senate Floor Amendment No. 2 House Concurs.'

DeLaRosa holds a BS from DePaul University.

DeLaRosa, a Democrat, was elected to the Illinois House in 2025 representing the 42nd District, succeeding Terra Costa Howard.

Illinois measures follow a multi-step legislative process, which includes bill introduction in either chamber, committee consideration, floor action, and votes in both the House and Senate, followed by the governor’s decision to sign or veto. The General Assembly works on a two-year cycle and typically only a portion of the thousands of bills introduced each session become law.